GH - Guardant Health, Inc.
The U.S. Food and Drug Administration (FDA) on Wednesday approved Guardant Health Inc.'s (NASDAQ:GH) Guardant360 Liquid CDx test, expanding the company's blood-based comprehensive genomic profiling capabilities for patients with advanced cancer.
The Food and Drug Administration approved Guardant Health's newest blood cancer test Wednesday, and the stock leaped to a three-month high.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardan
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions for patients with advanced cancer. Guardant360 Liquid CDx is the largest FDA-approved liquid biopsy panel, assess.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs w.
Guardant Health, Inc. delivered strong results in the first quarter, with accelerating revenue growth supported by the MRD and screening businesses. GH's Quest Diagnostics partnership, product upgrades, and expanded reimbursement are set to sustain strong fundamentals and revenue diversification. While Guardant's losses are still sizeable, the company is on a clear path to profitability, driven by the scaling on the MRD and screening businesses.
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.49 per share a year ago.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: Reported total revenue of $301.7 million, an increase of 48%, driven by: Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47%.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor.
First Financial Bancorp maintains a return on tangible common equity in the high teens, and we were able to buy the stock at an attractive valuation. We purchased shares of Guardant Health, as recent due diligence highlighted a stable competitive environment and underscored a number of positive catalysts for the company over the next several years. We exited our position in Dynatrace, Inc. to redeploy capital to other higher conviction names following the broad software de-rating.
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent's oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platf.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2026 Healthcare Conference in Las Vegas, NV Fireside chat on Tuesday, May 12th at 10:40 a.m. Pacific Time William Blair 46th Annual Growth Stock Conference in Chicago, IL Presentation on Tuesday, June 2nd at 9:20 a.m. Central Time Jefferies 2026 Global Healthcare Conference in New Yo.
Guardant Health, Inc (NASDAQ:GH) shares are trading lower on Tuesday after the U.S. Food and Drug Administration (FDA) announced a review of AstraZeneca Plc's (NASDAQ:AZN) application for camizestrant for advanced breast cancer.
B. Metzler seel. Sohn and Co. AG purchased a new stake in shares of Guardant Health, Inc. (NASDAQ: GH) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,918 shares of the company's stock, valued at approximately $911,000. Other hedge funds and
Assetmark Inc. lifted its stake in shares of Guardant Health, Inc. (NASDAQ: GH) by 48.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,718 shares of the company's stock after acquiring an additional 6,461 shares during the quarter. Assetmark Inc.'s holdings in
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be.